Priya Bhardwaj

Dr. Priya Bhardwaj

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
CJCamilla H B Jespersen
Camilla H B Jespersen
JKJohanna Krøll
Johanna Krøll
PBPriya Bhardwaj
Priya Bhardwaj
BWBo Gregers Winkel
Bo Gregers Winkel
PJPeter Karl Jacobsen
Peter Karl Jacobsen
PWPeter E Weeke
Peter E Weeke
Reduced psychological health is associated with adverse patient outcomes and higher mortality. We aimed to examine if a Brugada syndrome (BrS) diagnosis and symptomatic disease presentation were associated with an increased risk of new-onset depression or anxiety and all-cause mortality. All Danish patients diagnosed with BrS (2006–2018) with no history of psychiatric disease and available for ≥6 months follow-up were identified using nationwide registries and followed for up to 5 years after diagnosis. The development of clinical depression or anxiety was evaluated using the prescription of medication and diagnosis codes. Factors associated with developing new-onset depression or anxiety were determined using a multivariate Cox proportional hazards regression model. Disease manifestation was categorized as symptomatic (aborted cardiac arrest, ventricular tachycardia, or syncope) or asymptomatic/unspecified at diagnosis. A total of 223 patients with BrS and no history of psychiatric disease were identified (72.6% male, median age at diagnosis 46 years, 45.3% symptomatic). Of these, 15.7% (35/223) developed new-onset depression or anxiety after BrS diagnosis (median follow-up 5.0 years). A greater proportion of symptomatic patients developed new-onset depression or anxiety compared with asymptomatic patients [21/101 (20.8%) and 14/122 (11.5%), respectively, P = 0.08]. Symptomatic disease presentation (HR 3.43, 1.46–8.05) and older age (lower vs. upper tertile: HR 4.41, 1.42–13.63) were significantly associated with new-onset depression or anxiety. All-cause mortality in this group of patients treated according to guidelines was low (n = 4, 1.8%); however, 3/4 developed depression or anxiety before death. Approximately, one-sixth of patients with BrS developed new-onset depression or anxiety following a diagnosis of BrS. Symptomatic BrS disease manifestation was significantly associated with new-onset depression or anxiety.

4 April 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
CJCamilla H. B. Jespersen
Camilla H. B. Jespersen
JKJohanna Krøll
Johanna Krøll
PBPriya Bhardwaj
Priya Bhardwaj
CHCarl Johann Hansen
Carl Johann Hansen
JSJesper Svane
Jesper Svane
PWPeter E. Weeke
Peter E. Weeke
Background: Patients with Brugada syndrome (BrS) are recommended to avoid drugs that may increase their risk of arrhythmic events. We examined treatment with such drugs in patients with BrS after their diagnosis. Methods and Results: All Danish patients diagnosed with BrS (2006–2018) with >12 months of follow‐up were identified from nationwide registries. Nonrecommended BrS drugs were grouped into drugs to “avoid” or “preferably avoid” according to http://www.brugadadrugs.org . Cox proportional hazards analyses were performed to identify factors associated with any nonrecommended BrS drug use, and logistic regression analyses were performed to examine associated risk of appropriate implantable cardioverter defibrillator therapy, mortality, and a combined end point indicating an arrhythmic event of delayed implantable cardioverter defibrillator implantation, appropriate implantable cardioverter defibrillator therapy, and mortality. During a median follow‐up of 6.8 years, 93/270 (34.4%) patients with BrS (70.4% male, median age at diagnosis 46.1 years [interquartile range, 32.6–57.4]) were treated with ≥1 nonrecommended BrS drugs. No difference in any nonrecommended BrS drug use was identified comparing time before BrS diagnosis (12.6%) with each of the 5 years following BrS diagnosis ( P >0.05). Factors associated with any nonrecommended BrS drug use after diagnosis were female sex (hazard ratio [HR]) 1.83 [95% CI, 1.15–2.90]), psychiatric disease (HR, 3.63 [1.89–6.99]), and prior use of any nonrecommended BrS drug (HR, 4.76 [2.45–9.25]). No significant association between any nonrecommended BrS drug use and implantable cardioverter defibrillator therapy (n=20/97, odds ratio [OR], 0.7 [0.2–2.4]), mortality (n=10/270, OR, 3.4 [0.7–19.6]), or the combined end point (n=38/270, OR, 1.7 [0.8–3.7]) was identified. Conclusions: One in 3 patients with BrS were treated with a nonrecommended BrS drug after BrS diagnosis, and a BrS diagnosis did not change prescription patterns. More awareness of nonrecommended drug use among patients with BrS is needed.

15 April 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
DDDavid Duncker
David Duncker
CLChristophe Leclercq
Christophe Leclercq
HPHelmut Purerfellner
Helmut Purerfellner
VWVictor Waldmann
Victor Waldmann
Stefan SimovicStefan Simovic
Stefan Simovic
JMJosé L Merino
José L Merino
The European Heart Rhythm Association (EHRA) was created on 2 September 2003 as the first registered branch of the European Society of Cardiology (ESC) with a mission of ‘improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances’. Over the years, EHRA has become the leading European network and one of the most influential organizations worldwide for heart rhythm specialists and allied professionals. After 20 years of initiatives, exchanges, and continuous growth it is time to look back to measure the road travelled. This article reflects upon the history of EHRA, and its major achievements and looks to the future of the society (Figure 1).

3 August 2022 in JACC: Case Reports
Verified
Journal Article
Open access
PBPriya Bhardwaj
Priya Bhardwaj
NSNiels Kjær Stampe
Niels Kjær Stampe
CJCamilla H.B. Jespersen
Camilla H.B. Jespersen
JTJacob Tfelt-Hansen
Jacob Tfelt-Hansen
BWBo Gregers Winkel
Bo Gregers Winkel
We present the case of a relative of a patient with catecholaminergic polymorphic ventricular tachycardia. This relative underwent a standard (Bruce) exercise stress test (EST), which had normal results. He then underwent our modified “sprint” EST, with positive results. This report underlines how the sprint EST may provoke arrhythmias better than the standard Bruce EST. (Level of Difficulty: Advanced.)

23 July 2021 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
PBPriya Bhardwaj
Priya Bhardwaj
CVChristoffer Vissing
Christoffer Vissing
NSNiels Kjær Stampe
Niels Kjær Stampe
KRKasper Rossing
Kasper Rossing
ACAlex Hørby Christensen
Alex Hørby Christensen
BWBo Gregers Winkel
Bo Gregers Winkel
Background: AARS2 encodes the mitochondrial protein alanyl-tRNA synthetase 2 (MT-AlaRS), an important enzyme in oxidative phosphorylation. Variants in AARS2 have previously been associated with infantile cardiomyopathy. Case summary: A 4-year-old girl died of infantile-onset dilated cardiomyopathy (DCM) in 1996. Fifteen years later, her 21-year-old brother was diagnosed with DCM and ultimately underwent heart transplantation. Initial sequencing of 15 genes discovered no pathogenic variants in the brother at the time of his diagnosis. However, 9 years later re-screening in an updated screening panel of 129 genes identified a homozygous AARS2 (c.1774C > T) variant. Sanger sequencing of the deceased girl confirmed her to be homozygous for the AARS2 variant, while both parents and a third sibling were all found to be unaffected heterozygous carriers of the AARS2 variant. Discussion: This report underlines the importance of repeated and extended genetic screening of elusive families with suspected hereditary cardiomyopathies, as our knowledge of disease-causing mutations continuously grows. Although identification of the genetic etiology in the reported family would not have changed the clinical management, the genetic finding allows genetic counselling and holds substantial value in identifying at-risk relatives.

2 February 2026 in EP Europace
Verified
Journal Article
Open access
DSDorte Stavnem
Dorte Stavnem
PBPriya Bhardwaj
Priya Bhardwaj
RJReza Jabbari
Reza Jabbari
TEThomas Engstrøm
Thomas Engstrøm
LBLia Evi Bang
Lia Evi Bang
BWBo Gregers Winkel
Bo Gregers Winkel
Coronary artery spasm can be life-threatening. Clinically significant complications include myocardial infarction, ventricular arrhythmias, and sudden cardiac arrest. Although challenging to diagnose, new international guidelines have been published to guide the diagnosis of coronary artery spasm when this is the suspected cause of cardiac arrest. The aim of this review is to consider existing knowledge for the diagnosis and management of coronary artery spasm in survivors of sudden cardiac arrest. Twenty-seven original research articles (written in English) involving a total of 1541 survivors of sudden cardiac arrest associated with coronary artery spasm form the basis of this review. Most cohorts included >75% male participants with a mean age range of 45–63 years. A positive family history or coronary risk factors of coronary artery disease are not commonly found, albeit many survivors are smokers (ranged 17–100% across cohorts). Provocative testing for coronary spasm was reported in 25 of the evaluated papers, but the indications for testing were inconsistently specified. A high recurrence rate (up to 45%) of life-threatening ventricular arrhythmias was reported, and implantable cardioverter-defibrillator placement varied markedly. In conclusion, diagnosing coronary artery spasm as a cause of sudden cardiac arrest is challenging. The pathophysiological understanding is limited. Knowledge gaps include the incidence and prevalence, as well as the usefulness of provocative testing in survivors. More data are needed regarding patient risk stratification, indications for implantable cardioverter-defibrillator insertion, and optimal pharmacological therapy.